REG - Physiomics PLC - Collaborative Services Agreement

PhysiomicsAnnouncement

26/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230426:nRSZ4257Xa&default-theme=true

RNS Number : 4257X  Physiomics PLC  26 April 2023

26 April 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Collaborative Services Agreement

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting
oncology drug development and personalised medicine solutions, announces the
signature of a Collaborative Services Agreement with ValiRx's wholly owned
subsidiary Inaphaea BioLabs Limited.

The agreement recognises the synergy between Inaphaea's growing capabilities
as a translational contract research organisation (tCRO®) providing in-vitro
laboratory-based services and Physiomics' in-silico capabilities for advanced
statistical analyses, machine learning techniques, data handling and
visualisation, as well as biological modelling.

Under the agreement, service users of Inaphaea will be able to benefit from
Physiomics capabilities in a single service contract with Inaphaea.  Designed
to offer a seamless integration of data generation and data interpretation,
this collaborative method of working provides benefits to both companies as
well as to the service users.

Dr Jim Millen, CEO at Physiomics commented "The Collaborative Service
Agreement will expand the scope of our core consulting business to discovery
stage projects and improve our access to clients focused on earlier stages of
drug development, while at the same time supporting Inaphaea's own service
offering.  The synergy is clear and both the scientific and commercial
ambitions of our two companies are well matched.  We look forward to working
closely with ValiRx through this initiative"

Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative Services Agreement is
the first step towards converting Inaphaea into a true tCRO®.  The
Physiomics modelling skills will enable our clients to interpret and build on
the data generated within the Inaphaea facility.  I am delighted to be able
to offer this additional service module to our clients.  This additional
value-added service will be available to our first service users, with
benefits expected to increase as more complex data generation technologies are
added to our capabilities"

This announcement is released by Physiomics plc and contains inside
information for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 (MAR), and is disclosed in accordance with the Company's obligations
under Article 17 of MAR.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes for Editors

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 projects, over 40
targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDZGZDDKRGFZM